A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I:R1a—[O]v-(-A-L-)m-A-[O]v—R1b Iwherein A, L, R1a, R1b, m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.